Wyniki wyszukiwania:

Brexit has significantly reshaped pharmaceutical product submissions by separating the UK from the EU's centralized regulatory framework. Before Brexit, the European Medicines Agency (EMA) oversaw marketing authorizations, ensuring harmonized access across member states. Now, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) independently regulates medicines, requiring separate applications for UK and EU markets. This has led to duplication of dossiers, increased costs, and potential delays in patient access to innovative medicines. The loss of EU funding, research...

This book presents a comprehensive study on the stability of rifampicin, a first-line anti-tuberculosis drug, through method development, validation, and characterization of its degradation products. It begins with an overview of tuberculosis, rifampicin's pharmacological profile, and the importance of stability-indicating methods in pharmaceutical quality control. Using HPLC and LC-MS techniques, the study optimizes chromatographic conditions and develops a validated stability-indicating method as per ICH guidelines. Forced degradation experiments under acidic, alkaline, oxidative,...